Posttreatment Management of Cushing's Disease

A. Prete, R. Salvatori

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Transsphenoidal surgery is the first-line treatment for Cushing's disease. Successful removal of the adrenocorticotropic hormone-secreting pituitary tumor requires cautious follow-up because of the postoperative onset of adrenal insufficiency. Furthermore, possible surgical complications, such as diabetes insipidus and pituitary insufficiency, may occur. Despite an overall remission rate between 25% and 100% after primary surgery, disease persistence and recurrence are yet major clinical problems, and second-line therapies (alone or in combination) have to be considered, such as a wait-and-see approach, repeated neurosurgery, radiotherapy, radiosurgery, medical therapy, or adrenal surgery. Each of these approaches has strengths and limitations, and the choice has to be tailored to each clinical case, according to clinical, biochemical, and radiological data. Finally, despite persistent remission, long-term effects of hypercortisolism can affect the cardiovascular system as well as the skeletal system and the brain, with detrimental long-term sequelae.

Original languageEnglish (US)
Title of host publicationCushing's Disease
Subtitle of host publicationAn Often Misdiagnosed and Not So Rare Disorder
PublisherElsevier Inc.
Pages135-167
Number of pages33
ISBN (Electronic)9780128043905
ISBN (Print)9780128043400
DOIs
StatePublished - Jan 1 2017

Keywords

  • Adrenal insufficiency
  • Adrenalectomy
  • Crooke's cell
  • Cushing's disease
  • Diabetes insipidus
  • Hypercortisolism
  • Hypopituitarism
  • Nelson's syndrome
  • Radiosurgery

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Posttreatment Management of Cushing's Disease'. Together they form a unique fingerprint.

  • Cite this

    Prete, A., & Salvatori, R. (2017). Posttreatment Management of Cushing's Disease. In Cushing's Disease: An Often Misdiagnosed and Not So Rare Disorder (pp. 135-167). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-804340-0.00009-7